ICU

SeaStar Medical Holding Corporation (NASDAQ:ICU) is a Denver-based medical device company that went public in March 2021. The company specializes in developing extracorporeal therapies designed to treat hyperinflammation and cytokine storm in critically ill patients. SeaStar focuses on targeting the cellular mechanisms that drive systemic inflammation, which can cause direct tissue damage and trigger cascading immune responses that worsen patient outcomes in intensive care settings.